Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOGETHER-PsA
NCT06588296Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Primary completion
- Nov 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tirzepatide in psoriatic arthritis (PsA) and obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction at 36 weeks. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)obesity
Beyond the preview
Go deeper on NCT06588296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588296.